



26 September 2017

## **ASX ANNOUNCEMENT**

# **Penthrox is recommended for use in all UK ambulances.**

Medical Developments International Ltd (ASX: MVP) is delighted to advise the Joint Royal Colleges Ambulance Liaison Committee (JRCALC) has issued its new pain management clinical practice guidelines for UK ambulance services teams. The JRCALC guidelines now recommend the use of Penthrox® for adults with injuries causing moderate to severe pain.

MVP CEO Mr. John Sharman said: “We are delighted with this achievement. MVP and Galen have been waiting on the formal adoption of Penthrox by JRCALC since the beginning of 2017 and now that Penthrox has been recommended for use, it is our collective expectation that Penthrox will soon be used by every ambulance service in the UK. This recommendation is a significant achievement for the future of Penthrox in the UK and it will add significantly to the market potential for Penthrox®.

MVP’s UK and Ireland distributor is Galen whose Managing Director, David Bennett, commented “We welcome the inclusion of Penthrox on the JRCALC guidelines and are delighted that it is now confirmed as an option for effective pain management. This is a timely inclusion, as it follows the addition of Penthrox to the pre-hospital emergency care council (PHECC) guidelines in Ireland earlier this year. We are hopeful that the updated JRCALC guidelines will provide a confidence boost to the remaining UK ambulance services and pre-hospital teams yet to adopt Penthrox and we look forward to continuing to work with emergency response teams across the UK to provide optimal patient care.”

### Enquiries:

John Sharman  
Chief Executive Officer  
Medical Developments International Ltd  
03 9547 1888

David Williams  
Chairman  
Medical Developments International Ltd  
0414 383 593



### **About Pentrox**

Pentrox is a non-opioid, non-addictive, inhaled analgesic indicated in Australia for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Pentrox has been used for more than 40 years in Australia and is now sold into 16 countries with circa 6.0 million units sold. There is growing interest in Pentrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

### **About Medical Developments International Ltd**

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, an analgesic product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defense Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

### **About Galen**

Galen is a leading UK specialty pharmaceutical sales and marketing company, and has a significant presence in the UK and Irish markets. Galen is part of the Almac group which has in excess of 3,000 employees worldwide and is headquartered in Northern Ireland. Galen's knowledge of the target markets in the UK and Ireland will allow it to establish Pentrox as the leading product in self-administered trauma pain relief in the hospital and pre-hospital environments.